Is Net Medical Xpress Solutions, Inc. overvalued or undervalued?

Jun 25 2025 08:26 AM IST
share
Share Via
As of October 1, 2023, Net Medical Xpress Solutions, Inc. is considered undervalued with a P/E ratio of 15.2 and a P/B ratio of 1.8, trading at a discount compared to peers like Teladoc and Amwell, while also outperforming the Sensex.
As of 1 October 2023, Net Medical Xpress Solutions, Inc. has moved from fair to attractive in its valuation. The company appears to be undervalued based on its current performance metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Return on Equity (ROE) of 12%.

In comparison to peers, Teladoc Health, Inc. has a P/E ratio of 25.4, while Amwell has a P/B ratio of 3.1, indicating that Net Medical Xpress is trading at a discount relative to these competitors. Additionally, the stock has shown a stronger performance compared to the Sensex, reinforcing the notion of its undervaluation.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
What does Net Medical Xpress Solutions, Inc. do?
Jun 22 2025 06:13 PM IST
share
Share Via